1. Home
  2. ZNTL vs ACB Comparison

ZNTL vs ACB Comparison

Compare ZNTL & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.63

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$4.06

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZNTL
ACB
Founded
2014
2013
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
289.0M
232.3M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
ZNTL
ACB
Price
$2.63
$4.06
Analyst Decision
Buy
Analyst Count
5
0
Target Price
★ $6.60
N/A
AVG Volume (30 Days)
★ 858.8K
792.2K
Earning Date
05-07-2026
06-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.03
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$6.31
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.21
$2.56
52 Week High
$6.95
$6.67

Technical Indicators

Market Signals
Indicator
ZNTL
ACB
Relative Strength Index (RSI) 22.35 59.25
Support Level $2.09 $3.27
Resistance Level $2.69 $4.15
Average True Range (ATR) 0.19 0.13
MACD -0.05 -0.01
Stochastic Oscillator 4.18 59.68

Price Performance

Historical Comparison
ZNTL
ACB

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.

Share on Social Networks: